← Back to Search

SweetGoals App for Type 1 Diabetes

N/A
Waitlist Available
Led By Catherine Stanger, Ph.D.
Research Sponsored by Trustees of Dartmouth College
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participants must use a glucometer or continuous glucose monitor compatible with Glooko.
Be between 18 and 65 years old
Must not have
Diabetes diagnoses other than T1D (Type 2 Diabetes, Maturity Onset Diabetes of the Young/MODY)
Use of any medications known to impact glycemic control (oral or injectable corticosteroids, beta-blockers, antipsychotic medications such as risperidone)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up +12 months
Awards & highlights
No Placebo-Only Group

Summary

This trial will test an app and web intervention designed to help young adults with Type 1 diabetes better manage their blood sugar levels. The app provides self-monitoring tools and goal-setting assistance, while the web intervention offers health coaching and incentives for adherence.

Who is the study for?
This trial is for young adults with Type 1 diabetes who have had the condition for over 18 months and an A1c level of at least 7.5%. They must have seen their diabetes doctor in the last six months and use a glucose monitor compatible with Glooko. It's not for pregnant or breastfeeding individuals, those with severe illnesses like cystic fibrosis, severe cognitive issues, psychiatric conditions that affect participation, other types of diabetes, or if they're on certain meds that affect blood sugar.
What is being tested?
The study tests a digital intervention called SweetGoals app aimed at improving blood sugar control in Type 1 diabetics. Everyone gets the core app features focused on self-monitoring and goal setting. Additionally, it will evaluate whether incentives for sticking to treatment plans and web-based health coaching can further improve outcomes.
What are the potential side effects?
Since this trial involves using an app along with coaching and incentives rather than medication or medical procedures, there are no direct side effects as typically associated with drugs or surgery. However, participants may experience stress or frustration related to technology use or lifestyle changes encouraged by the program.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I use a Glooko-compatible glucose monitoring device.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have been diagnosed with a type of diabetes that is not Type 1.
Select...
I am not taking medications that affect blood sugar levels.
Select...
I do not have a severe illness like cystic fibrosis that would stop me from participating.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~+12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and +12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
HbA1c
Secondary study objectives
Glucose
Problem solving

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

4Treatment groups
Experimental Treatment
Group I: App plus IncentivesExperimental Treatment2 Interventions
SweetGoals app + incentives=yes + coaching=no
Group II: App plus Coaching plus IncentivesExperimental Treatment3 Interventions
Sweetgoals app + incentives=yes + coaching=yes
Group III: App plus CoachingExperimental Treatment2 Interventions
Sweetgoals app + incentives=no + coaching=yes
Group IV: App onlyExperimental Treatment1 Intervention
Sweetgoals app only
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Coaching
2016
Completed Phase 3
~5600
Incentives
2018
Completed Phase 2
~4280

Find a Location

Who is running the clinical trial?

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
2,446 Previous Clinical Trials
4,331,532 Total Patients Enrolled
Trustees of Dartmouth CollegeLead Sponsor
27 Previous Clinical Trials
10,971 Total Patients Enrolled
Catherine Stanger, Ph.D.Principal Investigator - Trustees of Dartmouth College
Trustees of Dartmouth College
2 Previous Clinical Trials
126 Total Patients Enrolled

Media Library

SweetGoals app Clinical Trial Eligibility Overview. Trial Name: NCT04646473 — N/A
Type 1 Diabetes Research Study Groups: App only, App plus Incentives, App plus Coaching, App plus Coaching plus Incentives
Type 1 Diabetes Clinical Trial 2023: SweetGoals app Highlights & Side Effects. Trial Name: NCT04646473 — N/A
SweetGoals app 2023 Treatment Timeline for Medical Study. Trial Name: NCT04646473 — N/A
~31 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top